Arizona Urological Society

AZUS Annual Meeting Post-Meeting Take-home Notes

By Aqsa Khan, M.D., AZUS Program Chair
Assistant Professor
Mayo Clinic, Department of Urology

July 30-Aug 1, 2021: El Conquistador Resort, Tucson, AZ


Single Port Robotics [Dr. Mark Tyson]:

  • Single port robotic surgery offers several advantages: pain control, bleeding
  • Disadvantages: length of surgery time, ?cost, limited mobility, no assistant
  • Part of a phylogenetic tree of robotic surgery
  • Tips for single port:
    • Keep camera port above the instruments
    • 4cm incision 3cm above umbilicus
    • Use an assistant port (esp. early), and make sure to place it at least 5cm away from incision
    • Use a Ray-Tec to assist with retraction
    • Grip strength on all instruments is the same (don’t have some that are stronger or weaker)
  • You can use incision to do the diversion extracorporeal, then redeliver, redock and connect intracorporeal (hybrid approach)
  • Future recommendations for instruments: vessel sealer, Cobra

 

Orgovyx Oral ADT [Dr. Ganesh Raj]:

  • Review of the history of ADTs in advanced CaP
  • Relugolix (FDA approved 2020) – GnRH antagonist
  • Treatment considerations in androgen deprivation therapy:
    • Limits testosterone effects all over, not just in the prostate
    • Side effects of ADH: cardiovascular disease, diabetes, osteoporosis
      • NCCN recommends optimizing conditions pre-treatment to limit risks after treatment (diabetes, CV disease, osteoporosis)
    • Route of administration are depot injection, implants, or an ORAL pill
  • Only FDA approved oral ADT for advanced prostate cancer (Relugolix)
    • Can prolong QT interval (not to be used in congenital known prolonged QT interval, or on a drug that can cause prolonged QT)
    • Mech of action: block LH/FSH release from pituitary because blocks GnRH receptor
    • HERO study: Phase 3 study: Orgovyx vs Leuprolide (360mg day one then 120mg once a day vs. 22.5mg SC q 3 mon)
      • 1st endpoint: testosterone
      • Inclusion criteria: serum T >150ng/dL, serum PSA >2, ECOG 0/1
      • Exclusion: significant CV disease (MI within 6 months), arrhythmias
      • N 622 (orgovyx) vs 308 (Lupron)
    • Sustained T suppression:
      • 7% suppression at 48 weeks compared to 88% Lupron
    • Works very quickly. 48hrs becomes castrate, compared to 3-4 weeks with Lupron.
    • Suppression less than 20, higher with org compared to Lupron
    • At 3 months, 92% average PSA reduction.
    • One of key warnings, after medication is stopped after week 48, there was a more rapid rise in T back to lower normal levels compared to Lupron.
    • Significant adverse events: rates higher in Lupron
    • Lupron causes continuous higher risk in CV events, compared to Orgovyx.
    • Nonserious adverse events (hot flashes), similar
    • Can be w/wo food. Take same time. Swallow whole
    • Avoid oral P-gp inhibitors (omeprazole). If must be on one of these can take a short 2-week break on the orgovyx to take the other medicine, and then restart
  • Summary
    • Once a day drug
    • 3 pills the first day, then 1 pill per day
    • rapid T suppression, rapid T recovery
    • Relatively well tolerated
    • Decreased risk of CV side effects
  • Patient support program available

 

Reconstructive Surgery & New Techniques [Dr. Sunchin Kim]:

  • Pre-op workup
    • Let strictures heal for a few months
      • SPT
      • PCNT
    • Robotic ureteral reimplant success 80-100% (compared to open 90% success)
    • Robotic Boari : success 75-100%
  • Reimplant
    • Post op care: stent 4-6 weeks, foley 5-10 days
      • f/u renal scan 3, 9, 18 months
    • Non-transecting side-to-side reimplant as an alternative to reimplant.
  • Boari flap
    • How much capacity is lost ?
      • 500mL capacity goes to 394mL (lose ABOUT 100CC)
    • Nice to know the bladder capacity beforehand (measure anesthesia if need to)
  • Buccal Mucosa Graft Ureteroplasty
    • Robotic approach described in 2015, now multiinstitutional experiences being reported
    • ICG indocyanine green can help identify the location of the stricture
    • Buccal graft 1.5cm width (compared to 2cm for urethroplasty)
  • Appendix for ureteroplasty
    • Preferred for the R side.
      Good for distal strictures
    • Less mucous production
    • Smaller diameter allows for less urine pooling
    • Downsides: length is unknown, can still make some mucous, rare but can have some strictures
    • Can be done as substitution OR onlay
  • Single port might be a great tool for reconstructive surgeries.
    • Comes with Firefly technology

 

Updated AUA Guidelines on Metastatic Prostate Cancer [Dr. Parminder Singh]:

  • Biochemical Recurrence w/o Mets after Local Treatments Exhausted
    • PSMA Scan: as PSA number goes up to 1.5-2, PSA PET positivity rate also goes up.
      • If PSA is 0.2, PET positivity rate is 42%, which goes up to 95% when PSA is around 2.
        • Much different than before when PSA needed to be much higher before you can detect recurrence.
      • CONDOR study: presented as ASCO 2020: About 85% true positivity rate for true recurrence.
    • Recommendation:
      • Use novel PET-CT scans (e.g. Fluciclovine, choline, PSMA) in pts with PSA recurrence after failure of local therapy as an alternative to conventional imaging or in setting of negative conventional imaging.
      • (can help find micro-metastatic disease)
    • Metastatic Hormone-Sensitive Prostate Cancer
      • Standard of care is moving to combination therapy (ADT + 2nd generation agents)
        • Hormonal therapy: Abiraterone (+prednisone), bicalutamide, enzalutamide
        • Chemo: docetaxel, cabazitaxel
      • Fatigue is difficult to manage and should be discussed with the patients.
      • STAMPEDE trial: abiraterone for CaP not previously treated with hormone therapy
        • High-risk (pT3+, PSA 40) – rapidly rising PSA after local therapy (surgery/xrt).
      • Chemotherapy worked as well as Lupron alone, which used to be the standard of care 10 years ago.
        • High-volume disease: this is a good alternative in patients (esp. patients with coverage issues) – can go onto Lupron later.
      • Newly Diagnosed mHSPC Recommendations:
        • Combination ADT (Abiraterone/Apalutamide/Enzalutamide) or ADT + chemo as 1st line
        • Can add RT to low volume disease patients
        • Single oral agent is not recommended
        • Genetic counseling
        • First generation oral anti-androgens should not be offered as 1st line
      • Non-metastatic Castrate Resistant Prostate Cancer:
        • PT you would have given ADT post prostatectomy or XRT for high risk disease and PSA is rising (becoming castrate resistant without any evidence of disease)
        • Darolutamide: the only med approved for this indication
        • Recommendations:
          • Clinicians should offer apalutamide, darolutamide, of enzalutamide with continued ADT
          • To nmCRPC patients at high risk for developing metastatic disease (PSADT<10mo)
          • No role for chemo or immunotherapy
          • Observation is appropriate for PSADT>10mo
          • Imaging followup in 6-12 mo.
        • Metastatic Castrate-Resistant Prostate Cancer
          • Consult oncologist
        • Bone Health
          • Prevention treatment: weight-bearing exercises to advanced CaP on ADT
          • High risk fracture risk due to bone loss, recommend preventative therapies with bisphosphonate or denosumab and referral to doc for OP management
          • Prescribe bone-protective agents (denosumab or zoledronic acid) for mCRPC with bony mets to prevent skeletal-related events

Second Generation Ant-Hormonal Agents:

Ultrasound-Guided Percutaneous Nephrolithotomy [Dr. David Zhou]:

  • Increase in number of urologists getting their own access for PCNL.
  • Difference in outcomes if urologists get their own access?
    • LOS, readmissions, transfusion, 2nd operation within 90 days lower if urologists get access
  • Learning curve for PCNL is 60 cases (fluoroscopy PCNL, not US PCNL)
  • Pull pannus over if doing supine positioning and tape it.
  • Technique for access:
    • Dorsal lithotomy, 5F angiocatheter, highlight the anatomy, advance needle to contralateral axilla
    • 2 fingerbreadths below the ribs and lateral to paraspinous
  • US PCNL
    • Advantages:
      • Lower radiation exposure
      • Real-time visualization of adjacent structures
      • Easier to identify most posterior calyx
      • Shorter learning curve
    • Tips/steps:
      • Orient US probe in a head (upper)-to-foot (lower) position
      • Place probe in mid-axillary line
      • Angle probe parallel to 11th rib to eliminate the rib shadow
      • KEY: Visualize your kidney
        • Longitudinal (insert needle at one end of the probe which is the short side)
      • Dilating under US – tough, needs experience. If need to bring in fluoro to do it safely, do it.
      • Dilation method is important:
        • Balloon dilator: readily see the tip of balloon dilator
        • Metal dilator: can be trickier
      • Tips:
        • Know the US machine!!!
          • “Depth” button is usually the knob (zooms kidney in and out)
          • “Gain” corresponds to the level of the US machine, buttons on the side of the machine
          • Optimize the trajectory

 

Interesting Cases:

  • Modified Martius Ventral Flap Urethroplasty for female stricture
  • IVC Tumor Supra-Diaphragmatic Tumor Thrombus responding to Immunotherapy in a Jehovah’s Witness patient

 

Update on Erectile Dysfunction & Investigational Treatments [Dr. Peter Burrows]:

  • Newer treatment -> 2010: Staxyn; 2012: Stendra
  • We need a treatment for ED, not just treating the
  • Old paradigm:
    • 1st line: PDE-5 inhibitors
    • 2nd line: VED, ICI, MUSE
    • 3rd line: IPP
  • 2018 AUA ED Tx Guidelines
    • 1st Line: lifestyle changes
    • 2nd line: Shared decision-making regarding risks/benefits with man and his partner
  • W/u: glucose, HbA1c, Testosterone, Lipids
  • Treat T deficiency
    • T deficiency is not ideal as monotherapy for ED (unless they are young men, have mild ED, or have a very low baseline T)
  • Unmet Needs 2021
    • What’s the cure?
    • Why did medicines stop working?
  • Low Intensity Shock Wave Therapy
    • Used in other fields (shows faster and reproducible healing)
    • Focal shock waves, NOT radial acoustic shockwaves
    • High intensity 50-100 MPa –focal destruction
    • Acoustic waves AKA radial are pneumatic: affordable (20-30k), but no data says there is an improvement on this compared to focal linear waves
      • Gainswave™: not a machine but a marketing machine
    • LSWT for Peyronie’s doesn’t change curvature but did improve the pain associated with the disease
    • LSWT: Mechanism of action by induce a shock ->
      • Recruit stem cells, recruit wound healing, recruit resident stem cells
      • Reduces inflammatory mediators: TNFa, TNFb, IL-1, IF-g
      • Decreased macrophage infiltration, increased M2 wound-healing Isotype
      • Induces angiogenesis by increased VEGF and angiopoietin
    • In penile rat studies, shows improvement of intracavernosal pressure
    • LSWT Randomized Human Trials
      • 7 trials (N of the studies 30-90s)
        • Outcome: change of >4 in IIEF score:
        • Meta-analysis: shows some benefit of LSWT compared to placebo.
          • Problem:
            • How many shocks?
            • How often?
            • What machines
            • Fails if lower number shocks/session
          • AUA Guidelines consider this investigational
        • Stem Cell Therapy
          • Animal models showed great promise (diabetic model and cavernosal nerve injury model)
          • Regenerative Medicine clinics have gone out of business $10-15k.
          • Part of the problem is how do you keep the stem cells within the penis.
          • Stem cells: adipose, placental, umbilical, bone marrow mononuclear
          • AUA Guidelines considers it experimental.
        • Platelet Rich Plasma (P-shot)
          • Easy, peripheral draw mix w Ca gluconate. Inject 3-5cc. Charge $500-1000/time.
          • No meaningful clinical studies.
          • One study from 2018: N=4. Claim improvement of IIEF by 4.14.
          • AUA Guidelines considers it experimental, should be under research protocols and with IRB approval

 

[Dr. Waleed Ikram]:

  • Improving on current imaging protocols to identify factors that are better to distinguish between MIBC and NMIBC on contrast CT scan.  Worked with computer scientists at ASU to extract better information from the CT scans.

Diamond Level

Sun Oncology
Myovant Sciences
Boston Sci. Corp.


Abbvie
Astellas Pharma
Boston Sci. Corp.
Cellay
Coloplast
Dendreon
Dornier MedTech
ENDO
Exosome Diagnostics
HealthTronics
Karl Storz
Laborie
MDxHealth
Myovant Sciences
Myriad Genetics
Neotract Teleflex
Next Med
Pacific Edge Diag.
Radiology LTD
Sun Oncology
Travere Therapeutics
UroGen Pharma
Urovant